RS504393
SIGMA/SML0711 - ≥98% (HPLC)
Synonym: 6-Methyl-1′-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one; RS-504393
CAS Number: 300816-15-3
Empirical Formula (Hill Notation): C25H27N3O3
Molecular Weight: 417.50
Linear Formula: C25H27N3O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| Quality Level | 100  |
| solubility | DMSO: 1 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Application: | RS504393 has been used in mass spectrometry. |
| Biochem/physiol Actions: | RS504393 helps to increase the analgesic potency of morphine and buprenorphine in neuropathic rats. RS504393 has the ability to block the upregulation of pronociceptive factors, like IL-1 (interlukin 1) β, IL-18 (interlukin 18), IL-6 (interlukin 6) and inducible nitric oxide synthase (iNOS), that are induced by chronic constriction injury (CCI). |
| Biochem/physiol Actions: | RS504393 is a highly selective CCR2 chemokine receptor antagonist. RS504393 inhibits MCP-1 chemotaxis and ischemia-reperfusion injury in kidneys. |
| Features and Benefits: | This compound is featured on the Chemokine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P261 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |